To use this site, please disable the ad blocking feature and reload the page.
This website uses cookies to collect information about your visit for purposes such as showing you personalized ads and content, and analyzing our website traffic. By clicking “Accept all,” you will allow the use of these cookies.
Users accessing this site from EEA countries and UK are unable to view this site without your consent. We apologize for any inconvenience caused.
Reuters file photo Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020.
Reuters
13:04 JST, May 11, 2023
May 11 (Reuters) – The U.S. Food and Drug Administration approved Otsuka Pharmaceutical’s 4578.T brexpiprazole to treat agitation in patients with Alzheimer’s on Thursday, making it the first approved drug for the indication, the company said in a statement.
The decision comes after an advisory panel in April voted 9-1 that the company had enough data to identify the population in whom benefits from the treatment outweigh its risks.
Patients with Alzheimer’s sometimes show signs of extreme aggression or become restless and anxious as their brain loses its ability to negotiate with new stimulus as a result of the disease.
Presently in the U.S., such patients are calmed down using non-pharmacological strategies first, only to be followed by off-label treatment with antipsychotics and anti-depressants in worse scenarios.
The approval of brexpiprazole is based on two late-stage studies, which showed significant improvement in calming agitated patients with Alzheimer’s, when compared with a placebo.
Brexpiprazole, co-developed with Danish drugmaker Lundbeck HLUNb.CO, was previously approved in the U.S. to treat adults with major depressive disorder and schizophrenia.
